Triangulation of measles vaccination data in the United Kingdom of Great Britain and Northern Ireland

Michael Edelstein,a Joanne White,a Antoaneta Bukasa,a Vanessa Saliba a & Mary Ramsay a

Objective To illustrate how data triangulation involving routine data sources can optimize data usage and provide insights into vaccine programme effectiveness by considering measles vaccination and disease incidence data in England.

Methods We obtained data on measles, mumps and rubella (MMR) vaccine coverage in birth cohorts from 1985 to 2016 from child health records and adjusted for under-ascertainment and catch-up campaigns. We assumed that the population had no natural immunity and that vaccine effectiveness was 95% for one dose and 99.75% for two doses. Vaccinations done outside the routine schedule and in people who entered England after the age of immunization were identified from primary care records. Measles susceptibility was defined as the percentage of individuals who were not immune despite all vaccination activities. We triangulated measles susceptibility and incidence data.

Findings Median susceptibility was 4.6% (range: 1.2–9.2). Among cohorts eligible for two MMR vaccine doses, those born between 1998 and 2004 were most susceptible. Measles incidence was highest in these cohorts. Data from primary care and child health records were comparable for cohorts after 2000, suggesting that little supplementary vaccination took place. For cohorts before 2000, primary care data quality was insufficient for accurately estimating coverage.

Conclusion Triangulating routine data on measles vaccination coverage and disease surveillance provided new insights into population immunity and helped identify vulnerable groups, which was useful for prioritizing public health actions to close gaps in immunity. This approach could be applied in any country that routinely records vaccine coverage and disease incidence.

Introduction

A considerable amount of immunization coverage and surveillance data are available nationally, regionally and globally.1 Often, however, these data could be better used to aid decision-making on national and subnational immunization programmes. Particularly where a disease is close to being eliminated and the remaining few percent of susceptible individuals are being targeted, the need for accurate data increases as vaccine coverage increases.2 Synthesizing data from two or more sources (i.e. data triangulation) is a pragmatic approach to optimizing the use of existing data, thereby improving data quality and gaining insights into the performance of vaccine programmes.1 In this study, we used the example of measles in England to illustrate how the triangulation of routine data sources, namely different sources on coverage of the combined measles, mumps and rubella (MMR) vaccine and measles incidence data, can help evaluate data quality and provide estimates of population immunity, which can be used to inform a national measles elimination strategy. As these data sources are available in most settings and for many diseases, with varying degrees of granularity and quality, our approach should be broadly replicable.

Measles is a viral infection transmitted by the respiratory route and one of the most contagious human diseases.3 In 2016, approximately 90 000 deaths were attributable to the disease globally,4 down from more than 550 000 in 2000 thanks to the accelerated roll-out of measles immunization programmes.4 The commitment to eliminate measles (and rubella) is an important part of global efforts to improve health and reduce inequality. To achieve and maintain elimination, the World Health Organization (WHO) recommends that countries attain 95% coverage with two doses of measles-containing vaccine by the time children are 5 years of age.5 Modelling suggests that measles can be eliminated in most contexts if the proportion of children younger than 5 years susceptible to measles is less than 15% and the proportion of susceptible individuals aged 5 years and older is less than 5%.6

In England, before measles vaccine was introduced in 1968, 160 000 to 800 000 cases of measles were notified and around 100 deaths from acute disease were recorded each year.7 After the combined MMR vaccine was introduced in 1988, coverage rapidly reached 90% and disease incidence fell to a very low level. In 1994, a large catch-up programme was undertaken with measles–rubella vaccine and in October 1996, a second MMR vaccine dose was added.7 However, in 1998 a British doctor published a now-discredited study suggesting a link between MMR vaccine and autism.8 The resulting intense media interest had a substantial impact on MMR vaccine coverage, which dropped to about 80% in the late 1990s and early 2000s and took many years to recover.9 Since this fall, several catch-up campaigns have been implemented to address gaps in population immunity. Measles cases continued to rise and in 2006, endemic transmission became re-established in the United Kingdom of Great Britain and Northern Ireland. The incidence peaked at 3.2 per 100 000 population in 2012 and decreased to 1.0 per 100 000 in 2016.10 The United Kingdom is committed to measles elimination and has developed a national strategy in line with the European Vaccine Action Plan 2015–2020.11,12 Since 2012, coverage for the first MMR vaccine dose in children aged 24 months has been consistently over 90%.6 In 2016 and 2017, coverage for the first dose in children aged 5 years reached 95% for the first time.7 Since 2016, imported cases of measles have led to several outbreaks, with some limited spread in the population, particularly among individuals who missed the MMR vaccine when they were young.

a National Infection Service, Public Health England, 61 Colindale Avenue, London NW9 5EQ, England.
Correspondence to Michael Edelstein (email: Michael.edelstein@phe.gov.uk).
Submitted: 27 December 2018 – Revised version received: 7 June 2019 – Accepted: 19 June 2019 – Published online: 23 August 2019

doi: http://dx.doi.org/10.2471/BLT.18.229138
were younger and in undervaccinated communities. Overall, the incidence of measles in England quadrupled between 2017 and 2018.

**Routine coverage and surveillance data in England**

Vaccine coverage in England is estimated by two methods. The first uses data from local Child Health Information Systems, which provide data to the cover of vaccination evaluated rapidly (COVER) programme. The second involves an online platform called ImmForm that automatically extracts immunization data from approximately 95% of primary care facilities (i.e. general practices).

The COVER programme is designed to collect data on coverage by specific target ages (i.e. by children’s second and fifth birthdays) and because it includes the entire population eligible for vaccination, provides the most accurate estimates of coverage at the time of data collection. As coverage is not routinely assessed again, COVER data will not accurately reflect the current status of a given birth cohort many years later. Vaccines given at an older age may not be recorded and neither the numerator nor denominator in the coverage calculation will include individuals who arrived in England after their fifth birthday. Nevertheless, COVER data are used for reporting to WHO on the WHO and United Nations Children’s Fund’s (UNICEF’s) Joint Reporting Form.

By contrast, ImmForm data represent vaccine coverage recorded by general practices at the time of data extraction and include anyone in a specific birth cohort who was registered with the practice at that time (i.e. 2017 to 2018 for our study). Consequently, the data should cover vaccinations given either through routine vaccination programmes, during national catch-up campaigns, opportunistically, or outside England to any individual of any age.

The accuracy of ImmForm data depends on the quality and completeness of clinical coding at each facility, these characteristics are known to have the greatest influence on immunization data quality globally. In the United Kingdom, clinicians are legally required to report suspected measles cases to the public health services. In addition, national surveillance systems require all suspected cases to be confirmed by laboratories using either an immunoglobulin-M antibody test on a serum or oral fluid specimen or a polymerase chain reaction technique.

**Data triangulation**

Data triangulation involves the synthesis of two or more data sources with the aim of assisting programme planning and decision-making. The process can identify and address limitations in any single data source or data collection method. In addition, deeper insights can be achieved by examining complementary data and putting them into a broader context. A recent report from a WHO-commissioned expert group on immunization data quality recommended that data triangulation should become the default approach to data analysis and use in its Expanded Programme on Immunization.

The aim of our study was to use the example of measles elimination in England to demonstrate how data sources that are routinely available as part of the Expanded Programme on Immunization can be synthesized to improve vaccination data quality and to generate new information, for example on measles susceptibility and gaps in immunity, that can help guide decision-making on vaccine policy.

**Methods**

In calculating the proportion of the English population susceptible to measles, we assumed a vaccine effectiveness of 95% for one MMR vaccine dose and 99.75% for two doses. In addition, we assumed there was no natural immunity because the level of circulating disease in the country over the past 30 years was low.

To estimate coverage of routine immunization for each birth cohort between the year from April 1985 to March 1986 (i.e. 1985–1986) and the year from April 2015 to March 2016 (i.e. 2015–2016), we used COVER data on the first and second MMR vaccine doses. Data collected at children’s fifth birthdays were generally available for birth cohorts from 1992–1993 until 2012–2013. We used data collected at the second birthday for individuals in birth cohorts after 2012–2013, who were too young during our study period to have had coverage of two doses assessed at 5 years of age, and for individuals in birth cohorts before 1992–1993, who were born before the second dose was included in the vaccination schedule. We applied a 50% coverage underestimate correction factor to COVER estimates. This percentage was based on a study that examined the extent of underestimation by checking the vaccination status of individuals not recorded as vaccinated in Child Health Information Systems.

Further, to consider the possibility that the 50% correction factor was too high, we examined the effect of a 25% correction factor in a sensitivity analysis.

Several birth cohorts included in the study were eligible for supplementary immunization in national catch-up campaigns (Table 1). Coverage data have been published for the 1994 and 2013 campaigns, for other campaigns, we used the best estimates from Public Health England (unpublished data). Fig. 1 describes how we determined the level of protection from measles among cohorts that were eligible for participation in catch-up campaigns. To ascertain the level of opportunistic vaccination after the routine vaccination age and outside of catch-up campaigns, we triangulated vaccine coverage data from the COVER programme (i.e. routine vaccination data only) with data from ImmForm, which potentially captures any vaccinations given up to the time of data extraction.

For each birth cohort, we calculated susceptibility (S) to measles, which was defined as the percentage of individuals in the birth cohort who had not been vaccinated or who were probably not immune despite routine, supplementary or opportunistic vaccination, using the equation:

\[
S = 100 - \left[ (X \cdot 0.9975) + (Y \cdot 0.95) \right]
\]

(1)

Where X is the percentage of birth cohort who received ≥ 2 vaccine doses and Y is the percentage of birth cohort who received 1 dose. Then, using the size of the population in each age band in 2017 obtained from the Office of National Statistics, we calculated the number of susceptible individuals in the population and overall population susceptibility. Susceptibility in each birth cohort was compared to the target immunity level required to keep the reproductive number (Rₚ) below one and, therefore, interrupt transmission in the population (Rₚ is the number of
| Birth cohort | Applicable catch-up campaign | Routine vaccination coverage, % | Adjusted routine vaccination coverage, % | Proportion susceptible to measles, % | Estimated no. of susceptible individuals in cohort in 2017 | Immunity level sufficient to interrupt transmission? |
|--------------|------------------------------|-------------------------------|-----------------------------------------|-----------------------------------|---------------------------------------------|-----------------------------------------------|
| 2015–2016    | None                         | NA                            | NA                                      | 91.2                              | NA                                          | 9.2                                           |
| 2014–2015    | None                         | NA                            | NA                                      | 91.6                              | NA                                          | 9.0                                           |
| 2013–2012    | None                         | NA                            | NA                                      | 91.6                              | 91.0                                        | 91.0                                          |
| 2012–2011    | None                         | NA                            | NA                                      | 91.8                              | 91.6                                        | 91.6                                          |
| 2011–2010    | None                         | NA                            | NA                                      | 92.8                              | 92.0                                        | 92.0                                          |
| 2010–2009    | None                         | NA                            | NA                                      | 93.8                              | 93.0                                        | 93.0                                          |
| 2009–2008    | None                         | NA                            | NA                                      | 94.2                              | 94.0                                        | 94.0                                          |
| 2008–2007    | None                         | NA                            | NA                                      | 94.2                              | 94.0                                        | 94.0                                          |
| 2007–2006    | None                         | NA                            | NA                                      | 94.2                              | 94.0                                        | 94.0                                          |
| 2006–2005    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2005–2004    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2004–2003    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2003–2002    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2002–2001    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2001–2000    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 2000–1999    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1999–1998    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1998–1997    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1997–1996    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1996–1995    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1995–1994    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1994–1993    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1993–1992    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1992–1991    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1991–1990    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |
| 1990–1989    | None                         | NA                            | NA                                      | 94.6                              | 94.0                                        | 94.0                                          |

(continues...)

Table 1. Estimated vaccination coverage and individuals susceptible to measles, by birth cohort, England, 1985–2016.
Table 1 shows whether each cohort achieved this target or not. To further validate our susceptibility estimates, we compared the age-specific incidence of laboratory-confirmed cases of measles by year of diagnosis (restricted to cases with an onset between 2010 and 2018) with age-specific susceptibility. We focused on age-specific incidence and susceptibility rather than on annual incidence to identify reported cases that occurred in birth cohorts eligible for vaccination and to help us discover underprotected groups that could be targeted by practical changes to vaccination programmes (for example, by identifying appropriate age groups for a catch-up campaign).

All susceptibility calculations were performed using Microsoft Excel (Microsoft Corporation, Redmond, United States of America). All coverage and surveillance data were collected through national routine surveillance systems and the study was conducted using aggregated data as part of routine surveillance activities. No specific funding or formal ethical approval was required.

Results

Table 1 shows coverage of the first and second MMR vaccine doses in birth cohorts between 1985–1986 and 2015–2016. The small differences between COVER and ImmForm estimates for birth cohorts between 2000–2001 and 2012–2013 (Fig. 2; ImmForm data at the children’s fifth birthday were not available after this date) suggest that little opportunistic vaccination took place after routine immunization and that no large groups of unvaccinated foreign-born children were registered with general practices in England. Since the quality of primary care data (i.e. ImmForm data) was low for birth cohorts before 2000–2001, coverage estimates were uncertain (Fig. 2).

Overall, measles susceptibility among people born between 1985 and 2016 was 4.6% (range: 1.2–9.2), which corresponds to 975,920 individuals in these birth cohorts in 2019 (Table 1). Of individuals who were eligible for the second MMR vaccine dose from October 1996 onwards, those born between 1998 and 2004 were in birth cohorts classified as not having a sufficiently high level of immunity to prevent measles transmis-
Discussion

Our application of data triangulation to measles vaccination in England, which considered data on vaccine coverage (including supplementary immunization) in individual birth cohorts and data on the age-specific incidence of measles, illustrates that the approach provides a pragmatic, simple and useful way of generating and validating disease susceptibility estimates. The concordance between data sources we observed for specific birth cohorts confirmed that data quality was high in those years, such information is helpful for evaluating data-driven targeted vaccination. In contrast, we found that coverage and incidence data were discordant for individuals in birth cohorts between 1989–1990 and 1991–1992, which suggested that one of the two sources was inaccurate. Discordant findings can trigger further investigation and lead to improved data quality.

The use of triangulation also enabled us to determine that, despite good coverage overall, there was a high proportion of susceptible individuals among those born between 1998 and 2004 (who were aged between 15 and 22 years in 2019), even after adjusting for coverage under-ascertainment. This finding was consistent with disease incidence data, which showed that most cases and outbreaks in recent years occurred in this age group. In England, where vaccine coverage is assessed using various methods, our synthesis of data from two different vaccine coverage sources led to insights into the vaccination status of the population. This data synthesis enabled us to estimate the magnitude of opportunistic vaccination, as well as evaluate the data quality of primary care vaccination records. For example, we found that data quality was not sufficient to accurately estimate vaccine coverage among adults born abroad.

In addition to the limitations inherent in both COVER and ImmForm data, the study had several other limitations. First, coverage data for catch-up campaigns were less accurate than for routine immunization. In particular, data were not collected for the 2008 catch-up campaign (unpublished regional evaluations suggest coverage was low). Second, a London-only, catch-up campaign took place in 2004 and achieved a minimum of 24% coverage for individuals born between 1985 and 2004. This campaign was not included in our study because it was regional. Consequently, susceptibility in eligible birth cohorts may have been overestimated at the national level. Third, coverage in national catch-up campaigns was assumed to be the same in all areas and eligible birth cohorts. Fourth, although 95% of general practices contributed to ImmForm data, the proportion varied between cohorts. Moreover, only 50% of practices reported data on cohorts born before September 1995. However, as these practices were spread across the country, coverage estimates for
these cohorts were unlikely to have been biased. Fifth, although COVER data included single-antigen measles vaccine for birth cohorts between 1985 and 1987, ImmForm data did not. This discrepancy may explain why estimated coverage in these birth cohorts was lower for ImmForm than COVER data (Fig. 2). Sixth, during the early to mid-2000s, a small number of parents opted to have their children vaccinated using a private, unlicensed, single measles vaccine. This vaccine was not included in either COVER or ImmForm data. A 2007 study involving children born in 2001 and 2002 estimated that use of this vaccine could have increased coverage for all measles-containing vaccines by around 2% in individuals born in the early 2000s.

When high-quality census data that can be linked to age-specific disease susceptibility estimates are available, the number of susceptible individuals currently in the population can be deduced, thereby enabling the size and timing of future outbreaks to be modelled. Data triangulation can improve the accuracy and precision of coverage estimates, which is vital in areas where coverage is high, and increase confidence in data. In contrast, a recent study that used incomplete and inaccurate information overestimated the number of susceptible individuals in England by a factor of 1.8.

Our analytical approach involved only routinely available data sources, which are not exclusive to the United Kingdom or other high-income countries. Any country that routinely records disease incidence and vaccine coverage could consider a similar approach for measles and other diseases. However, the value of the information produced will depend on the accuracy and precision of the data available and on knowledge of how data quality varies over time. A comprehensive report on improving immunization data quality and use that was recently presented to WHO's Strategic Advisory Group of Experts on immunization is available online. The report provides strategic guidance on improving data at the national level. In countries where data on individual years are not available, wider age ranges could be considered. Although the resulting insights would be less detailed, the analysis would still be useful for validating coverage and surveillance data and for identifying susceptible age groups. Currently, WHO is planning to publish a framework for, and guidance on, data triangulation to help countries routinely adopt the approach. One alternative to using routine data sources is to conduct much costlier and resource-intensive seroprevalence stud-
ies. In England, where the quality of both coverage and incidence data is relatively high, the added value of seroprevalence studies is limited. Current arrangements rely on residual blood samples from hospitals, which may not be representative of the general population, particularly for younger age groups.

Although national estimates of disease susceptibility can help identify at-risk birth cohorts, they may not reflect inequalities at the local level. In England, vaccine coverage varies by ethnicity, social deprivation and geographical location. Consequently, coverage is heterogeneous and the burden of measles and rubella falls disproportionately on specific communities. Herd immunity extends the benefits of national immunization programmes to unvaccinated individuals, thus intrinsically reducing inequalities, but its impact will depend on local and overall vaccine coverage and population mixing patterns. When a large number of unvaccinated individuals live in close proximity, their community becomes vulnerable to outbreaks. Better vaccine coverage across the whole population should be accompanied by targeted efforts to assess the risk, specific needs and characteristics of undervaccinated communities and, thereby, close any gaps in immunity.

In conclusion, triangulating existing data sources on routine vaccination coverage and vaccine-preventable disease surveillance can generate new insights into a population’s level of immunity and help prioritize public health actions aimed at closing gaps in immunity. Use of this approach in England helped establish that, despite achieving high MMR vaccine coverage, measles susceptibility in particular age cohorts was sufficiently high to sustain disease transmission. Nevertheless, susceptibility in all population subgroups cannot be estimated using routine data sources alone. Ad hoc studies are needed for undervaccinated groups, such as adults born abroad. Triangulating coverage and incidence data, in particular, is a useful way of maximizing the quality of data on vaccine-preventable diseases and should be used more widely. Forthcoming guidance from WHO and its partners on the triangulation of data from the Expanded Programme on Immunization will help countries improve data use and quality and, ultimately, help control vaccine-preventable diseases.

Competing interests: None declared.
Data triangulation and immunization policy

Michael Edelstein et al.

Data triangulation and immunization policy

Abstract

The objective was to illustrate how routine data triangulation of coverage and disease incidence data can provide new insights into population immunity and help identify susceptible populations. We applied this approach to data from routine immunization 2000 for the UK.

Methods

We obtained data from primary care and childhood health records. We identified the proportion of susceptible individuals and incidence by age, sex, and cohort. We estimated the proportion of people who would benefit from additional doses of MMR vaccine.

Results

The median susceptibility rate was 4.6% (range: 1.2–9.2). In the 1998 to 2004 birth cohorts, the majority of people were susceptible. We estimated that 99.75% of people born after the age of 2004 were susceptible. The results suggest that routine data triangulation of vaccination and disease incidence can provide new insights into population immunity and help identify susceptible populations.

Conclusion

Routine data triangulation of vaccination and disease incidence can provide new insights into population immunity and help identify susceptible populations. This approach could be applied to any country with regular data triangulation of vaccination and disease incidence.

Résumé

Triangulation des données relatives à la vaccination contre la rougeole au Royaume-Uni de Grande-Bretagne et d’Irlande du Nord

Objectif

Illustrer comment la triangulation des données incluant des sources de données ordinaires peut optimiser l'utilisation des données et donner une idée de l'efficacité du programme de vaccination en considérant des données relatives à la vaccination contre la rougeole et à l'incidence de la maladie en Angleterre.

Méthodes

Nous avons obtenu des données sur la couverture vaccinale contre la rougeole, les oreillons et la rubéole dans les cohortes de naissances de 1985 à 2016 à partir des dossiers médicaux des enfants. Nous avons comparé les cohortes antérieures à 2000, les cohortes ultérieures à 2000, et les cohortes avec le programme ROR.

Résultats

La sensibilité médiane était de 4,6% (étendue: 1,2–9,2). Parmi les cohortes MMR, les cohortes ne nées entre 1998 et 2004 étaient les plus sensibles. Nous estimons que 99,75% des personnes nées après l'âge de 2004 sont susceptibles. Ces résultats suggèrent que la triangulation de données de vaccination et d'incidence peut fournir des nouvelles perspectives sur l'immunité de la population et aider à identifier les populations vulnérables.

Conclusion

La triangulation des données ordinaires sur la couverture vaccinale et l'incidence de la maladie peut fournir des informations et des perspectives nouvelles sur l'immunité de la population et aider à identifier les populations vulnérables. Ceux-ci pourraient être appliqués dans tous les pays pour déterminer l'incidence de la maladie.

Resumen

Triangulación de datos de vacunación contra la sarampión en el Reino Unido

Objetivo

Ilustrar cómo la triangulación de datos proporciona nuevas perspectivas sobre la inmunidad de la población y ayuda a identificar grupos vulnerables. Aplicamos este enfoque a datos de vacunación y incidencia de enfermedad del Reino Unido.

Métodos

Obtuvimos datos de las vacunas de sarampión, el eritema y la rubéola de los registros de salud infantil. Identificamos el porcentaje de inmunidad en niños de diferentes cohortes, utilizando la triangulación de datos de vacunación y enfermedad. Estimamos el porcentaje de inmunidad para cada cohorte.

Resultados

El porcentaje de inmunidad se encontró entre 4.6% (1.2-9.2). En las cohortes MMR, las cohortes no nacidas entre 1998 y 2004 fueron las más inmunes. Estimamos que 99.75% de las personas nacidas después de 2004 son susceptibles. Estos resultados sugieren que la triangulación de datos de vacunación y enfermedad puede proporcionar nuevas perspectivas sobre la inmunidad de la población.

Conclusión

La triangulación de datos ordinarios sobre la vacunación contra la sarampión y enfermedad puede proporcionar nuevas perspectivas sobre la inmunidad de la población y ayuda a identificar grupos vulnerables. Este enfoque podría ser aplicado en todos los países para determinar la prevalencia de la enfermedad.

摘要

大不列颠及北爱尔兰联合王国的麻疹疫苗接种数据三角互证

目的

通过考虑麻疹、腮腺炎和风疹（MMR）疫苗接种覆盖率和疾病发病率数据的国家，我们可以提供有关疫苗计划效果的见解。

方法

我们从1985年至2016年的儿童健康记录中获得了出生队列中麻疹、腮腺炎和风疹（MMR）疫苗接种覆盖率的相关数据，并根据归因不足和弥补活动进行了调整。我们假设没有天然免疫力，并且一剂疫苗的有效率为95%，两剂疫苗的有效率为99.75%。在初级保健记录中，我们确定了在常规计划之外以及在免疫接种年龄后进入英国的人群中进行的疫苗接种。麻疹易感率是指不论各种免疫活动，非免疫人口所占的百分比。我们对麻疹易感率和发病率数据进行了三角互证。

结果

中位数易感率为4.6%（范围：1.2-9.2）。在符合两种MMR的疫苗剂量的队列中，1998年至2004年间出生的人群最易感染。麻疹发病率在这些队列中最高。2000年后，我们来自初级保健和儿童健康记录的数据在队列中具有可比性，表明很少进行补充疫苗接种。对于2000年以前的队列，初级保健数据质量不足以准确估算覆盖范围。

结论

麻疹疫苗接种覆盖率和疾病监测的三角互证数据针对人群免疫力提供了新的见解，并有助于识别易感群体，从而有利于优先考虑公共保健措施，缩小免疫差距。这种方法可以应用于任何经常记录疫苗覆盖率和发病率的国家。
Triangulación de los datos de vacunación contra el sarampión en el Reino Unido de Gran Bretaña e Irlanda del Norte

Resumen

Objetivo: Ilustrar cómo la triangulación de datos con fuentes rutinarias de datos puede optimizar el uso de los mismos y proporcionar información sobre la eficacia de los programas de vacunación al considerar la vacunación contra el sarampión y los datos de incidencia de la enfermedad en Inglaterra.

Métodos: Se obtuvieron datos sobre la cobertura de la vacuna contra el sarampión, los papeleras y la rubéola (SPR) en las cohortes de nacimiento de 1985 a 2016 a partir de los registros de salud infantil y se ajustaron para tener en cuenta las campañas de vacunación y de los errores por la falta de observaciones. Se asumió que la población no tenía inmunidad natural y que la efectividad de la vacuna era del 95% para una dosis y del 99,75% para dos dosis. Las vacunas realizadas fuera del horario de rutina y en personas que ingresaron a Inglaterra después de la edad de vacunación fueron identificadas en los registros de atención primaria. La susceptibilidad al sarampión se definió como el porcentaje de individuos que no eran inmunes a pesar de todas las actividades de vacunación. Se triangularon los datos de susceptibilidad e incidencia del sarampión.

Resultados: La mediana de susceptibilidad fue de 4,6% (rango: 1,2-9,2). Entre las cohortes elegibles para dos dosis de la vacuna triple viral, las que nacieron entre 1998 y 2004 fueron las más susceptibles. La incidencia de sarampión fue mayor en estas cohortes. Los datos de los registros de atención primaria y de salud infantil fueron comparables para las cohortes después de 2000, lo que sugiere que se realizó muy poca vacunación suplementaria. Para las cohortes anteriores a 2000, la calidad de los datos de atención primaria fue insuficiente para estimar con precisión la cobertura.

Conclusión: La triangulación de los datos de rutina sobre la cobertura de la vacunación contra el sarampión y la vigilancia de las enfermedades proporcionó nueva información sobre la inmunidad de la población y ayudó a identificar a los grupos vulnerables, lo que resultó útil para establecer prioridades en las medidas de salud pública a fin de subsanar las deficiencias en materia de inmunidad. Este enfoque podría aplicarse en cualquier país que registre de forma rutinaria la cobertura de la vacuna y la incidencia de la enfermedad.
12. European vaccine action plan 2015–2020. Geneva: World Health Organization, 2014. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/publications/2014/european-vaccine-action-plan-20152020-2014 [cited 2019 Jun 7].

13. Measles outbreaks across England. London: Public Health England; 2018. Available from: https://www.gov.uk/government/news/measles-outbreaks-across-england [cited 2019 Jun 7].

14. Laboratory-confirmed cases of measles, rubella and mumps, England: October to December 2018. London: Public Health England; 2019. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/791349/hp0819_mmr.pdf [cited 2019 Jun 7].

15. Amirhalingam G, White J, Ramsay M. Measuring childhood vaccine coverage in England: the role of Child Health Information Systems. Euro Surveill. 2012 04;17(16):20149. PMID: 22551461

16. Edelstein M, Crocker-Buque T, Tsang C, Eugenio O, Hopson T, Pebody R, et al. Extracting general practice data for timely vaccine coverage estimates: the England experience. Vaccine. 2017 09;123(38):5110–4. doi: http://dx.doi.org/10.1016/j.vaccine.2017.08.015 PMID: 28822644

17. Rivest P, Bédard L, Arruda H, Trudeau G, Remis RS. Risk factors for measles epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep CDR Rev. 1997 Feb 7;7(2):R17–21. PMID: 9046124

18. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J. 1991 Mar;10(2):883–8. PMID: 7757898

19. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J. 1991 Dec;10(2):883–8. PMID: 7757898

20. Simone B, Balasegaram S, Gobin M, Anderson C, Charlett A, Coole L, et al. Evaluation of the measles, mumps and rubella vaccination catch-up campaign in England in 2013. Vaccine. 2014 Aug 6;32(36):4681–8. doi: http://dx.doi.org/10.1016/j.vaccine.2014.05.077 PMID: 24996125

21. Gay N, Ramsay M, Cohen B, Hesketh L, Morgan-Capner P, Brown D, et al. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales. Arch Dis Child. 2007 Sep;92(9):786–9. doi: http://dx.doi.org/10.1136/adc.2006.109223 PMID: 17412744

22. Letley L, Rew V, Ahmed R, Habersaat KB, Paterson P, Chantler T, et al. Tailoring immunisation programmes: using behavioural insights to identify barriers and enablers to childhood immunisations in a Jewish community in London, UK. Vaccine. 2018 07 25;36(31):4687–92. doi: http://dx.doi.org/10.1016/j.vaccine.2018.06.028 PMID: 29945634